Knowledge transfer is the exploitation of research findings to benefit society.
iMed.ULisboa strongly encourages knowledge transfer to produce an innovation footprint, adding economic value to the scientific quality of our results that funds further research. We emphasize a strong pro-commercialization culture leading to registration and maximal exploitation of patents, and collaborations with industry. We have a strong history of patent filling and licensing and creation of spin-offs; emphasis has been on new small molecules, antibody-derived therapeutics, delivery strategies, and methods of controlling cell fate.
iMed.ULisboa works regularly with pharmaceutical and biotechnology companies on collaborative research programs, and is further developing the provision of R&D services and technologies to industry as a priority of our activity.